Why the study?
Does a dose-adjusted polygenic risk model predict anthracycline-induced cardiotoxicity in patients receiving anthracyclines?
Does a dose-adjusted polygenic risk model predict anthracycline-induced cardiotoxicity in patients receiving anthracyclines?
A dose-adjusted polygenic risk model incorporating SLC28A3, UGT1A6, and RARG variants can help predict anthracycline-induced cardiotoxicity based on the administered dose.
Answers are grounded in this paper and cite their sources.
Does not support changing anthracycline regimens yet; leaves open prospective validation of dose-adjusted genetic risk models.
These findings suggest that the SLC28A3 variant imparts more significant protection for patients receiving higher anthracycline doses, whereas the UGT1A6 and RARG risk variants significantly increased the risk of cardiotoxicity at low anthracycline doses.
No takes yet. Share an insight, caveat, or question.
Siemens et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: